These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 6138375)

  • 1. Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism.
    Packer M
    J Am Coll Cardiol; 1983 Nov; 2(5):841-52. PubMed ID: 6138375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope.
    Packer M
    J Am Coll Cardiol; 1988 Nov; 12(5):1299-317. PubMed ID: 2844873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of positive inotropic agents for chronic heart failure: how have we gone astray?
    Packer M
    J Am Coll Cardiol; 1993 Oct; 22(4 Suppl A):119A-126A. PubMed ID: 8397231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure.
    Packer M
    Eur Heart J; 1988 Jun; 9 Suppl H():105-8. PubMed ID: 2901957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy of congestive heart failure. An evaluation of recent advances.
    Alpert MA
    Postgrad Med; 1987 May; 81(6):257-67. PubMed ID: 2883640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
    Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
    Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far.
    Packer M; Kessler PD; Lee WH
    Circulation; 1987 Jun; 75(6 Pt 2):V56-64. PubMed ID: 3552317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical management of chronic heart failure: inotropic, vasodilator, or inodilator drugs?
    Lang R
    Am Heart J; 1990 Dec; 120(6 Pt 2):1558-64. PubMed ID: 1978981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic agents for the management of congestive heart failure.
    Feldman AM
    Curr Opin Cardiol; 1994 May; 9(3):301-4. PubMed ID: 7914112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs in the treatment of heart failure.
    Brown L
    Clin Exp Pharmacol Physiol; 1995 Nov; 22(11):829-32. PubMed ID: 8593738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy or oral pirbuterol in severe chronic congestive heart failure: acute hemodynamic and long-term ambulatory evaluation.
    Awan NA; Needham K; Evenson MK; Hermanovich J; Joye JA; DeMaria AN; Mason DT
    Am Heart J; 1981 Sep; 102(3 Pt 2):555-63. PubMed ID: 7270402
    [No Abstract]   [Full Text] [Related]  

  • 12. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
    Weber KT; Janicki JS; Jain MC
    J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of vasodilator, inotropic or combined therapy for the management of heart failure.
    Cohn JN; Franciosa JA
    Am J Med; 1978 Jul; 65(1):181-8. PubMed ID: 685992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasodilators and inotropic agents in the treatment of congestive heart failure.
    Francis GS
    Semin Nephrol; 1994 Sep; 14(5):464-78. PubMed ID: 7997651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Milrinone: a positive inotropic vasodilator.
    Colucci WS; Jaski BE; Fifer MA; Wright RF; Braunwald E
    Trans Assoc Am Physicians; 1984; 97():124-33. PubMed ID: 6535335
    [No Abstract]   [Full Text] [Related]  

  • 17. New inotropic-vasodilating drugs in acute and chronic heart failure.
    Goenen MJ
    Ann Med Interne (Paris); 1986; 137(3):229-34. PubMed ID: 3767191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conceptual dilemmas in the classification of vasodilator drugs for severe chronic heart failure. Advocacy of a pragmatic approach to the selection of a therapeutic agent.
    Packer M
    Am J Med; 1984 Jun; 76(6A):3-13. PubMed ID: 6377886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.
    Cohn JN; Ziesche S; Smith R; Anand I; Dunkman WB; Loeb H; Cintron G; Boden W; Baruch L; Rochin P; Loss L
    Circulation; 1997 Aug; 96(3):856-63. PubMed ID: 9264493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.
    Packer M; Medina N; Yushak M
    Circulation; 1984 Dec; 70(6):1038-47. PubMed ID: 6388899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.